Survival analyses indicated that patients with high CD4 expression in the tumor compartment, dichotomized according to the median of its relative expression, had improved PFS (37.8 vs. 23 months, p = 0.042) and OS (81.2 vs. 42.9 months, p = 0.018). Here, CD4 is linked to neoplasm.